AmycretinInvestigational peptide · zenagamtide (formerly amycretin)
Amycretin, now called zenagamtide, has been studied in oral and injectable forms. Early weight-loss trials and a later oral diabetes trial answer different questions and should be read separately.
What is Amycretin?
Amycretin is now called zenagamtide. It is a single investigational peptide; the 2026 publication describes activity at GLP-1, amylin and calcitonin receptors. Counting receptor targets does not tell us how much clinical benefit each contributes. 3
How it works
Amycretin is now called zenagamtide. It is a single investigational peptide; the 2026 publication describes activity at GLP-1, amylin and calcitonin receptors. Counting receptor targets does not tell us how much clinical benefit each contributes. 3
Effects studied
Early clinical studies
The first oral study enrolled 144 participants across several parts; only the 60-person multiple-dose part lasted 12 weeks. Its main endpoint was adverse events. Weight change was exploratory, so it should not be presented as a large, long-term obesity trial. 1 The separate injection study enrolled 125 participants and followed different dose groups for up to 36 weeks. It found a weight-loss signal, but many participants withdrew, often for reasons unrelated to adverse events. That limits how confidently the estimates can be applied outside the trial. 2
Evidence: Small, formulation-specific trials
Type 2 diabetes
A 2026 phase 2 oral study in 186 adults with type 2 diabetes assessed HbA1c over 36 weeks. Its population and primary question differ from the earlier weight-loss studies. A published correction is linked to this paper and should be read with it. 3 4
Evidence: Phase 2; correction must accompany the paper
What does the evidence show?
Early oral/injection trials and a 2026 oral phase 2 diabetes trial; correction review pending
One molecule, an updated name
Amycretin is now called zenagamtide. It is a single investigational peptide; the 2026 publication describes activity at GLP-1, amylin and calcitonin receptors. Counting receptor targets does not tell us how much clinical benefit each contributes. 3
Why the formulation matters
The first oral study enrolled 144 participants across several parts; only the 60-person multiple-dose part lasted 12 weeks. Its main endpoint was adverse events. Weight change was exploratory, so it should not be presented as a large, long-term obesity trial. 1
The separate injection study enrolled 125 participants and followed different dose groups for up to 36 weeks. It found a weight-loss signal, but many participants withdrew, often for reasons unrelated to adverse events. That limits how confidently the estimates can be applied outside the trial. 2
Reading an early weight-loss result
A 2026 phase 2 oral study in 186 adults with type 2 diabetes assessed HbA1c over 36 weeks. Its population and primary question differ from the earlier weight-loss studies. A published correction is linked to this paper and should be read with it. 3 4
What larger studies can clarify
Gastrointestinal events were common in both early programmes. The 2026 oral trial also reported serious adverse events among active-treatment recipients; their occurrence alone does not establish that the drug caused them. Small trials cannot reliably exclude uncommon harms. 1 2 3
Safety & status
Gastrointestinal events were common in both early programmes. The 2026 oral trial also reported serious adverse events among active-treatment recipients; their occurrence alone does not establish that the drug caused them. Small trials cannot reliably exclude uncommon harms. 1 2 3
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Is amycretin a mixture of two medicines?
No. It is a single molecule. The newer publication describes GLP-1, amylin and calcitonin receptor activity. 3
Can oral and injected results be combined?
They should be reported separately because exposure, formulation and tolerability can differ.
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Gasiorek et al. (2025): First-in-human oral amycretin trial Primary research · PubMed abstract; full paper and supplements not reviewed; checked 2026-10-29
- Dahl et al. (2025): Subcutaneous amycretin phase 1b/2a trial Primary research · PubMed abstract; full paper and supplements not reviewed; checked 2026-10-29
- Mora et al. (2026): Oral zenagamtide in adults with type 2 diabetes, phase 2 Primary research · Current abstract; linked erratum identified, full correction not retrieved; checked 2026-10-29
- Lancet (24 October 2026): Correction to oral zenagamtide phase 2 paper Published correction · Erratum metadata and linkage verified; publisher full text blocked with HTTP 403; checked 2026-10-29
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.